Search This Blog

Wednesday, April 1, 2020

Futures off 3% after ugly first quarter

Risk-off sentiment is seeping into the markets once again, with traders deciding their next moves as the second quarter kicks off.
As of 3:00 a.m. ET, S&P 500 futures were down 3.6% and Dow futures were off more than 700 points, following a warning from President Trump that the coming weeks would be “very painful” and White House projections of 100K-240K U.S. coronavirus deaths.
The Dow already recorded its worst quarter since 1987 in Q1, while the S&P 500 logged its worst quarter on record, as the pandemic caused a nationwide shutdown of the economy.
What’s next? Moody’s ADP Employment data is expected to show an evaporation in job creation later today, while the latest manufacturing indexes will be released for March.
https://seekingalpha.com/news/3557069-futures-off-3-after-ugly-first-quarter

Teva prevails in migraine patent dispute; shares up 9%

The USPTO’s Patent Trial and Appeal Board has upheld three patents protecting Teva Pharmaceutical Industries’ (TEVA +9.0%) migraine med Ajovy (fremanezumab-vfrm) that were challenged by Eli Lilly (LLY -0.9%).
Lilly claimed that the patents, related to calcitonin gene-related peptide (CGRP)-targeting antibodies [(i.e., fremanezumab and Lilly’s Emgality (galcanezumab-gnlm)], were invalid since CGRP was a clinically validated target for treating migraine well before Teva filed its patent applications. Teva countered that the earlier work centered on research tools to better understand the science, not for developing an antibody.
Teva sued Lilly for infringement shortly after the latter received the FDA nod in September 2018 after which Lilly challenged the validity of the patents.
The companies’ civil suit is on hold until the patent office completes its reviews.
https://seekingalpha.com/news/3556858-teva-prevails-in-migraine-patent-dispute-shares-up-9

GE finally closes $20B Biopharma sale

General Electric (NYSE:GE) has finalized the sale of its BioPharma unit to Danaher (NYSE:DHR), giving its $20B, after accounting for taxes, fees and factored receivable balances.
The anticipated proceeds have been central to CEO Larry Culp’s efforts to chip away at GE’s debilitating debt load and help it recover from a deep slump in recent years.
The companies won approval from the Federal Trade Commission earlier this month for the deal, which was announced in early 2019.
https://seekingalpha.com/news/3557071-ge-finally-closes-20b-biopharma-sale

Tuesday, March 31, 2020

Mask middlemen: Pop-up brokers seek big paydays in frenzied market

Brian Kolfage, a Florida military veteran, recently convinced Americans to donate millions of dollars for a privately built wall on the U.S. southern border. Now he has jumped into a new venture: hawking millions of protective face masks that are in critically short supply during the coronavirus pandemic.

About a month ago, Kolfage formed a business called America First Medical, which offers on its website and in social media pitches to broker large-volume sales of high-grade masks known as N95s. He said he charges about $4 each – several times the pre-pandemic prices but a few dollars less than some hospitals, nursing homes and first responders are now paying.
Though he hasn’t yet found buyers, Kolfage says he’s found masks all over the world, including stockpiles hidden away in warehouses in Japan and Eastern Europe. If a deal goes through, he will collect a commission between 1% and 3%, depending on the size of the order, he said.
He said he’s performing a public service. “We’re the ones out there kissing the frogs and doing all the work that these hospitals and others can’t do,” Kolfage, 38, told Reuters. “We’re the ones making these connections. If the hospital wants to pay the money, that’s up to them.”
Kolfage aims to be one of the new mask middlemen. As the novel coronavirus has spread around the world, an improvised, chaotic market has sprung up. Brokers claim to have access to tens or even hundreds of millions of masks — generally outside the normal supply channels and at prices much higher than the former retail price of about $1 each.
High-volume deals – even with low-percentage commissions – could bring big paydays for the middlemen. And these brokers could help ease critical shortages if they succeed in encouraging manufacturers and traders sitting on scarce supplies to sell them where they’re needed.
But the frenzy also has broken down standard quality controls, opening the market to an influx of masks of uncertain origin and effectiveness, medical suppliers and healthcare industry officials say. As supplies run ever lower, hospitals and nursing homes are being deluged with offers, and some say they have no choice but to pursue the promising leads while hoping to sidestep the scams.
The hot commodity in the mask trade is the N95 device, sturdier than surgical masks and better able to filter out much smaller particles such as the coronavirus. Health experts say lower-quality or ill-fitting masks are more likely to let airborne pathogens through, exposing healthcare workers to a virus that has killed nearly 39,000 people across the globe and infected close to 800,000.
Reuters spoke to five new mask brokers, three in the United States and two in China, which is the world’s largest mask manufacturer and accounts for about half of global production. These middlemen described a wild marketplace, in which they seek to quickly connect sellers and buyers before competitors can move in and sell stockpiles out from under them.
Jake Mei, an owner of a pump supply firm in Houston, Texas, said in one LinkedIn posting that he had 8 million masks, two models made by industrial giant The 3M Company, for sale, at $4.10 to $4.20 a mask. “Good price and quick delivery!” he promised. In an interview, however, he said he’s having trouble finding inventory.
None of the middlemen would disclose suppliers or customers, and Reuters could not independently confirm their access to vast stashes. All said manufacturers were setting base prices, which they said accounted for the bulk of recent price increases.
Kolfage told Reuters that the masks he finds – which he says are not from China – are of good quality, certified by the U.S. Food and Drug Administration. And he’s not price gouging, he said, but rather charging a commission far lower than other brokers. Reuters is aware of prices higher than his, including those that New York Governor Andrew Cuomo recently said had risen from 85 cents to $7 apiece.
“This is just an impossible situation to manage,” Cuomo said publicly on March 22, ‘describing a bidding war over medical equipment thats pitting states against states, in which prices can rise within 20 minutes.
On March 23, President Donald Trump signed an executive order prohibiting hoarding and price gouging of medical supplies, and Attorney General William Barr said the Justice Department had launched a national task force to investigate such schemes.
If you “have a big supply of toilet paper in your house, this is not something you have to worry about,” Barr said at a White House briefing that day. “But if you are sitting on a warehouse with masks, you will be hearing a knock on your door.”
A U.S. Department of Justice spokesman declined to comment on the mask trade. The FDA did not comment, except to describe how it has eased some requirements during the crisis and opened the door to sales of masks that meet other countries’ standards. Betsy Lordan, a Federal Trade Commission spokeswoman, said there is no federal law against price gouging, and the FTC has not pursued such cases in past disasters.
Christian Fjeld, who worked on FTC legislation as a staffer in both the House and Senate, says a patchwork of state laws aim to stop companies from charging prices generally defined as “excessive” or “unconscionable.”
But “they are squishy terms,” said Fjeld, now vice president of ML Strategies, a Washington lobbying firm. If high prices are being set by suppliers in a scarce market, he said, it would be tough to make a case that the sellers are gouging.
‘STEALTH’ COMPANIES, COUNTERFEITERS AND PROFITEERS
Some mask brokers appear to be counterfeiters or selling substandard knock-offs, according to a major manufacturer, 3M of St. Paul, Minnesota, and a major hospital supplier, Premier Inc, of Charlotte, North Carolina.
Chaun Powell, Premier vice president of strategic supplier engagement, said some pitches from suppliers, offering masks by the millions of uncertain provenance, have struck the company as highly suspicious.
“Our stealth company is currently supplying bulk quantities” of N95 masks, said one pitch forwarded to Premier. “If you know of any buyers who would be interested, (the supplier would) love to cut you in on the transactions.” Premier declined to disclose the sender’s name.
Powell said his company has issued warnings to its customers about pop-up brokers. But he said some clients are considering these offers anyway, placing orders and hoping for the best.
“It really demonstrates the level of desperation in our supply chain,” he said. “They’re trying to evaluate which is better — to have a faulty mask or no mask.”
The pitches from mask brokers have poured in at an increasing rate as the shortage has grown critical, Powell said.
“In the past five days we’ve had 70 different solicitations,” he said on March 24. “It seems everybody has a friend or a cousin who knows somebody in China who is producing these masks.”
3M recently issued a public statement warning that products being marketed under its name could be counterfeit.
“3M has strict quality standards, and therefore products that have missing straps, strange odors, blocked valves, misspelled words, etc. are likely not authentic 3M respirators,” a company statement said.
One mainstream distributor said that legitimate 3M products also are being diverted out of normal channels by manufacturers or others who want to profit from runaway prices. “The question is, how did the stuff get diverted in the first place?” said Michael Einhorn, president of Dealmed, a supply company in Brooklyn, New York. “There’s something fundamentally wrong with the supply chain.”
“A million people in their garage” seem to have access to the products when authorized distributors do not, Einhorn said. “They’re flipping it to a guy, who’s flipping it to another guy. By the time it ends up in a hospital, 10 people have touched it and made money.”
3M said it has not raised its prices in the pandemic but says it can’t control what others are charging. On March 25, 3M Chief Executive Officer Mike Roman sent a letter to Attorney General Barr and other officials saying the company wanted to help crack down on counterfeiters and profiteers.
Kolfage and other brokers told Reuters they are running clean operations. Kolfage said buyers’ funds will be held in escrow by a law firm and the products inspected by an independent verification firm before any transaction closes.
SKIRTING SKETCHY OFFERS
The impromptu market thrives on scarcity. Two weeks ago, leaders of a trade group for nursing homes said thousands of their members were about to run out.
“There just isn’t enough out there,” said Dr. David Gifford, chief medical officer at the American Health Care Association.
A survey by Premier released last Wednesday showed that 25% of hospitals that responded said they were down to less than a day’s supply of masks.
The chaotic market compounds the challenges faced by besieged hospitals such as Holy Name Medical Center in Teaneck, New Jersey. Twenty-two Covid-19 patients have died at the facility, which now has 139 patients presumed to have the virus, according to hospital figures as of Sunday.
Staff members have been forced to go outside their normal supply chains to keep medical gear in stock, according to Adam Jarrett, chief medical officer.
One recent shipment of 1,000 masks turned out to be substandard and lacked FDA certification. The vendor agreed to replace them with good ones, he said.
Jarrett said his staff has been able to find enough to keep up a four-day supply while avoiding sketchy offers.
“Anyone who we think may have a product, we are chasing it down,” he said. “We’ve seen offers of a million masks, but you’ve got to buy all million, at $9 each”? or about nine times the pre-crisis level. “There are absolutely unscrupulous people out there doing bad (stuff), but we’ve been smart enough to steer clear of those.”
In non-emergency situations, manufacturers are required to submit lengthy applications to receive FDA certification, including test results and engineering drawings.
Given the shortage, the FDA recently said it would not object to the sale of masks for medical purposes that come from a variety of other countries even though they are not certified to meet U.S. standards.
‘LIKE THE STOCK MARKET’
The new mask brokerage business has roots abroad, where manufacturers are setting the base price and traders are snapping up scarce supplies.
An executive at a Shanghai trading firm said some traders there are sitting on stockpiles of tens of millions of masks. Those that are N95-standard and FDA-approved are “the unicorn” that everybody is looking for.
“These are traders that are basically just hoarding to see if the price goes up. It’s like the stock market,” said Justin Huang, chief operating officer of JH Consulting Group. “If they have an inventory that they got at two dollars, they can sell it now for four, or they can maybe sell it at five tomorrow.”
Businessman Paul Bhang, from the Chinese city of Hangzhou, said he recently plunged into the mask sales business with a friend.
“A lot of people are not qualified to do this – I’m not qualified,” he said. But Bhang said he needed the money and believes he can connect factories directly with buyers.”Whatever they produce daily, it’s sold out,” Bhang said. “The factories don’t care who customers are now.”
“In an ordinary situation,” he said, “we would go and check the factories and their documents, but now we can only see the photos.”
‘A SELLERS MARKET’
Another newcomer to the mask market is Kolfage.
A U.S. Air Force veteran who lives with his family in Florida, Kolfage lost his legs and right arm in a rocket attack during the Iraq war. After owning and selling right-wing news websites, he set up a fundraiser that capitalized on Trump’s quest to build a barrier on the U.S.-Mexican border, We Build the Wall https://www.reuters.com/investigates/special-report/usa-borderwall-business. The effort pulled in $25 million from donors starting in December 2018.
So far, Kolfage has built two wall sections on private land, in New Mexico and Texas. He said he didn’t take any compensation for a year but now is now being paid $10,000 a month as president of the nonprofit running the wall project.
In his new venture, he said, it’s all about speed. On March 3, the day his website was registered, Kolfage posted a picture on Instagram of piles of boxes labeled 3M sitting in a warehouse, saying he had 300 million N95s available to ship to the United States.
“…Trying to reach the U.S. government and arm up our docs with the proper equipment. Message me please,” he wrote, tagging Trump and the U.S. Department of Homeland Security.
The supplies, Kolfage said, were owned by a wealthy businessman who wanted to sell the whole lot for $3 each and triple his investment. “These were in Japan at the airport in Osaka ready to be loaded onto a plane,” said Kolfage, who according to 3M is not one of the company’s authorized dealers.
He couldn’t find a buyer fast enough. The opportunity is “long gone,” he told Reuters on Monday.
“It’s their sandbox,” he said of suppliers. “It’s a seller’s market right now on these things.”
https://www.marketscreener.com/PREMIER-INC-14383011/news/Special-Report-The-Mask-Middlemen-How-pop-up-brokers-seek-big-paydays-in-a-frenzied-market-30284473/?countview=0

Over 5,000 Surgery Centers Can Now Serve As Hospitals in COVID-19 Crisis

The Trump administration cleared the way Monday to immediately use outpatient surgery centers, inpatient rehabilitation hospitals, hotels and even dormitories as makeshift hospitals, health care centers or quarantine sites during the coronavirus crisis.
The Centers for Medicare & Medicaid Services announced it is temporarily waiving a range of rules, thereby allowing doctors to care for more patients.
Hospitals and health systems overwhelmed with COVID-19 patients will be able to transfer people with other medical needs to the nation’s 5,000 outpatient surgery centers, about half of which are affiliated with hospitals. This will give the country thousands of additional hospital beds and operating rooms, some of which have ventilators or anesthesia gas machines that could be repurposed as ventilators.
Outpatient surgery centers will be allowed to treat patients with other critical needs — such as serious injuries, cancer or heart attacks — unrelated to COVID-19, allowing hospitals to conserve scarce resources and reduce the risk of infection to these patients.
Until now, federal regulations allowed outpatient surgery centers to care for patients for a maximum of 24 hours.
“Transferring uninfected patients will help hospital staffs to focus on the most critical COVID-19 patients, maintain infection control protocols, and conserve personal protective equipment,” the agency said in a statement.
Many outpatient surgery centers had closed after being told to halt elective procedures. A coalition of anesthesiologists in recent weeks called for them to stop performing nonessential surgery and assist hospitals.
The waivers “will allow hospitals to save more lives” by performing “surgeries and procedures that can’t wait until the pandemic is over,” said Bill Prentice, CEO the Ambulatory Surgery Center Association, an industry group.
Before the CMS announcement, the California Ambulatory Surgery Association had expressed its willingness to help.
The outpatient centers “want to be part of the solution as the entire healthcare industry must rise to meet this enormous challenge,” said Michelle George, president of the California Ambulatory Surgery Association, in a statement issued Monday morning. “We have valuable resources to lend to this crisis — whether it is staff, space, equipment, supplies or other capabilities. ASCs are coordinating with the public health teams on local and regional levels to identify how their facilities can be utilized most effectively on a case by case basis.”
Advocates who have pushed for surgery centers to assist hospitals praised the move.
“This is a great step in fighting this pandemic,” said Dr. Adam Schlifke, an anesthesiologist and clinical assistant professor at Stanford University in California.
“We recognize that it’s going to be hard,” Schlifke said. “It’s extremely complicated, but we are here to support all the surgery centers that will need to convert as a result of this order.”
The waivers will allow hospitals to hire local physicians and health care providers to address potential surges; transfer critical equipment, including telemedicine equipment, to doctors’ offices; and provide meals and child care for their health care workers.
Hospitals will be able to triage sick patients at community locations, then send them to the most appropriate facility, according to CMS.
“Front-line health care providers need to be able to focus on patient care in the most flexible and innovative ways possible,” said CMS Administrator Seema Verma. “This unprecedented temporary relaxation in regulation will help the health care system deal with patient surges by giving it tools and support to create nontraditional care sites and staff them quickly.”
Even with additional facilities, hospitals and health care systems could run out of staff, especially as health providers become sick with COVID-19. Although surgery centers typically employ their own nurses, they tend to share surgeons with local hospitals.
More than a dozen states and health care associations had requested waivers. The CMS move means that other states will no longer need to apply for waivers.
Texas had taken the lead in recent days, even before the new announcement, by permitting hospitals to use off-site facilities. Texas Gov. Greg Abbott last week signaled his interest in using outpatient surgery centers to expand care by ordering them to tell the state how many ventilators they possess.
Among other sweeping changes:
  • Ambulances will be allowed to transport patients to outpatient surgery centers, community mental health centers, federally qualified health centers, physician’s offices, urgent care facilities and any locations furnishing dialysis services when a dedicated kidney failure treatment center isn’t available. Hospitals will be able to charge for services provided outside their four walls and emergency departments can use telehealth services to evaluate sick people.
  • Physician-owned hospitals can temporarily increase their number of licensed beds, operating rooms and procedure rooms, according to CMS.
  • Instead of going to crowded emergency rooms, patients could go to off-site locations to be evaluated by emergency health care providers using telemedicine. That change will help preserve space in the emergency room for those who need it most. CMS will allow health providers to treat more patients via apps or telephone and bill at the same rate as in-person visits.
  • Physician assistants and nurse practitioners will be allowed to order tests and medications that may have previously required a physician’s order, as long as state law allows it. Also, certified registered nurse anesthetists will no longer have to work under the supervision of a doctor, freeing up physicians to focus more on patients and less on supervising.
  • To reduce the need for patients with health problems unrelated to COVID-19 to go to a doctor’s office or hospital, doctors will be allowed to monitor patients remotely with devices that can measure a patient’s oxygen saturation levels using pulse oximetry.
Health care experts have been suggesting the administration offer such waivers for weeks. The country has “got to muster all reasonable facilities and personnel,” said Arthur Caplan, a bioethics professor at NYU Langone Medical Center. “The best way to ration is to avoid it by stretching resources and sharing.”
More Than 5,000 Surgery Centers Can Now Serve As Makeshift Hospitals During COVID-19 Crisis

Battelle deploys decontamination system for reusing N95 masks

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for personal protective equipment (PPE), allowing healthcare workers to clean and reuse scarce N95 respirator masks.
The system is currently operating at Battelle’s Ohio facility—capable of processing up to 80,000 masks per machine, per day, within what looks like a large metal shipping container—and has been working to help stretch supplies for the OhioHealth system based in Columbus.
Using concentrated hydrogen peroxide vapor, the filters are gassed for two and a half hours to destroy bacteria, viruses and other contaminants, including the novel coronavirus SARS-CoV-2. According to the company, the system can clean the same N95 mask up to 20 times without degrading its performance.
The FDA had first OK’d the use of the system on Saturday but initially limited its use to 10,000 masks per day, according to Republican Ohio Gov. Mike DeWine, who called on the agency to unlock the system’s full decontamination capacity. DeWine also said this would have limited Battelle’s plans to deploy machines to the hard-hit New York metro area as well as Washington state and Washington, D.C.
Within hours, and after President Donald Trump also urged the FDA to approve the equipment on Twitter, FDA Commissioner Stephen Hahn tweeted late Sunday evening that the agency had issued an amended authorization.
In the near term, Battelle’s facility plans to begin decontaminating respirator masks for three other central Ohio health systems this week.
Battelle previously engaged with the FDA from 2014 to 2016 to study the use of its decontamination machine in the midst of a potential pandemic and PPE shortage. Currently, the company is exploring its use outside of N95 masks to other equipment such as ventilator components.
https://www.fiercebiotech.com/medtech/battelle-deploys-decontamination-system-for-reusing-n95-masks

COVID-19: Race to repurpose everything from antiviral to anticancer discoveries

Jonathan Dordick, Ph.D., and his lab mates at Rensselaer Polytechnic Institute (RPI) weren’t thinking about coronaviruses when they initially developed their “viral trap,” a DNA-based nanotechnology designed to capture and kill viruses floating in the bloodstream. But as the COVID-19 pandemic started to unfold, they realized they may be able to transform their invention into a potential solution to the relentless virus—and they got to work on a plan to do so.
“We have something that can be tailored specifically to the virus,” said Dordick, professor of chemical and biological engineering at RPI, in an interview with FierceBiotechResearch. “There has been very rapid research that has come out in the last couple of months about the proteins on the surface of the coronavirus. Once we know their approximate location on the surface, and what the receptor is [on cells] that the virus targets, it allows us to very quickly tailor this DNA nanostructure” to COVID-19, he said. Dordick’s team has developed a research proposal, which includes testing the viral trap technology in animal models of COVID-19, he added.
RPI is one of several institutions stepping up with ideas of how to take existing research and pivot it toward potential solutions to COVID-19. And these ideas are not just bubbling up in academia. Some biotech startups are taking existing antiviral discoveries—or even technologies they initially developed to address very different diseases, like cancer—and offering to deploy them toward defeating the coronavirus.
It may take several months or even years for these efforts to bear fruit, at which point this pandemic may have ended, but that’s no deterrent, many scientists say. “We will see new viruses being passed from animals to humans again,” predicted Christian Peters, M.D., Ph.D., CEO of Pinpoint Therapeutics, in an interview with FierceBiotechResearch. Pinpoint is one of the companies that’s putting plans in place to target COVID-19. “We must have an armamentarium of different drugs with different mechanisms so we’re ready for the future that’s to come,” Peters said.

RPI’s viral trap is adaptable to a range of viruses due to its design, Dordick explained. The technology entails folding pieces of DNA into a five-point star that mimics the latching locations on human cells that viruses must bind to in order to infect their hosts. In a Nature Chemistry paper published in November 2019, they described how they used the folded DNA to rapidly detect the dengue virus in blood.
The next step would be to use the same nanotechnology platform to kill the virus once it’s snared in the trap. “In detecting the virus, we’re also preventing it from binding to its receptor,” he said. “We showed that the DNA binds to the proteins on the surface of the dengue virus, preventing them from infecting the target cell. In that way, we can inhibit the infection process.” Dordick’s team has shown that a similar approach is effective in preclinical models of influenza A and Zika virus, as well.
As for startup Pinpoint Therapeutics, it was founded on the discovery that drugs designed to combat the malaria virus may also have promise in fighting cancer—and now its scientists are taking their antiviral know-how and applying it to COVID-19. Pinpoint is developing drugs that inhibit PPT1, a pathway targeted by a class of antimalarial drugs known as chloroquines.
If that sounds familiar, it’s because President Donald Trump created a bit of an uproar earlier this month when he latched onto reports about the potential use of chloroquine against COVID-19 and said the U.S. would make it available by prescription “almost immediately.” Questions have since emerged about the effectiveness of the drug against the virus due to disappointing clinical trial results in China, but the FDA did issue emergency use authorization for the use of hydroxychloroquine in COVID-19 patients Monday.
Pinpoint’s approach revolves around a process called “autophagy,” in which cells recycle components so they can survive being attacked. Researchers at the University of Pennsylvania discovered that inhibiting PPT1 slows tumor growth—a finding that led to the formation of Pinpoint, which is now optimizing PPT1 inhibitors to test in cancer. Pinpoint has received seed funding from Kairos Ventures, which in February kicked in $1 million in debt funding to help accelerate the search for candidate drugs.
Peters said that the company’s scientific team realized inhibiting PPT1 would also interrupt the ability of COVID-19 to replicate. And because the drugs could have as much as 1,000-fold more potency than standard malaria treatments when it comes to inhibiting PPT1, the hypothesis is that they could be more effective against COVID-19 than hydroxychloroquine is.
Although it will take several months to complete the laboratory and animal studies needed to identify drug candidates against COVID-19, Peters believes the insights they gain will remain relevant, even if the pandemic has resolved by that time. “It’s important to look not just at the anti-viral components, but also at the anti-inflammatory properties that these drugs might have. The synergistic effects of less virus replication and less inflammation may actually be very beneficial in the treatment of coronaviruses.” And because there are so many viruses that are closely related to COVID-19, and there’s a risk that novel viruses will continue to emerge, Pinpoint’s scientists believe any new products that come from their research will find a place in the market, he said.

Some researchers who have devoted their careers to understanding coronaviruses are finding their expertise in high demand during this pandemic. One of them is Ralph Baric, Ph.D., professor of microbiology and immunology at the University of North Carolina (UNC) at Chapel Hill. Early discoveries in his lab led to Gilead Sciences’ remdesivir, the investigational antiviral that’s now in clinical trials for COVID-19. Gilead, meanwhile, is making the drug available on a compassionate use basis for patients fighting COVID-19.
Now, another COVID-19 candidate has emerged from Baric’s lab. The drug, called EIDD-2801, is being developed by Ridgeback Biotherapeutics and Emory University’s nonprofit biotechnology company Drug Innovations at Emory (DRIVE).
UNC and Emory researchers described EIDD-2801 last week in a study that was preprinted on the Cold Spring Harbor Laboratory site bioRxiv. The researchers reported that the drug has “broad spectrum antiviral activity” against COVID-19 and several related viruses, including MERS-CoV. In mice infected with MERS-CoV or SARS-CoV, the drug decreased the viral load and improved lung function, they reported in the study (PDF).
EIDD-2801 is a ribonucleoside analog that’s designed to prevent RNA viruses from replicating. Ridgeback was already preparing for clinical trials of the drug in influenza when it and DRIVE’s scientists “immediately recognized that EIDD-2801 had the potential for treating COVID-19,” George Painter, Ph.D., director of the Emory Institute for Drug Development and CEO of DRIVE, said in a statement.
The rapidly unfolding COVID-19 pandemic has inspired the scientific community to come up with solutions that will have the potential to save lives in the future, RPI’s Dordick said. “The key question after we get through this tragedy is, ‘how will we avoid it again?’” Dordick said. “Will we have to shut everything down again, or can we have directed therapeutic development? I think we’re learning the lesson that we need rapid vaccine development and rapid therapeutic development. We’re going to learn an awful lot about what we can do.”
https://www.fiercebiotech.com/research/covid-19-bio-researchers-race-to-repurpose-everything-from-antiviral-to-anticancer